CenterBook Partners LP Sells 6,998 Shares of Boston Scientific Corporation $BSX

CenterBook Partners LP lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 26.1% in the second quarter, HoldingsChannel.com reports. The firm owned 19,793 shares of the medical equipment provider’s stock after selling 6,998 shares during the period. CenterBook Partners LP’s holdings in Boston Scientific were worth $2,126,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in BSX. Brighton Jones LLC increased its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. Wedbush Securities Inc. boosted its stake in Boston Scientific by 5.7% during the 1st quarter. Wedbush Securities Inc. now owns 2,998 shares of the medical equipment provider’s stock valued at $302,000 after purchasing an additional 162 shares during the last quarter. Advisor OS LLC increased its holdings in Boston Scientific by 17.3% during the 1st quarter. Advisor OS LLC now owns 3,300 shares of the medical equipment provider’s stock worth $333,000 after purchasing an additional 486 shares in the last quarter. Journey Strategic Wealth LLC raised its stake in shares of Boston Scientific by 11.0% in the first quarter. Journey Strategic Wealth LLC now owns 3,277 shares of the medical equipment provider’s stock worth $331,000 after purchasing an additional 326 shares during the last quarter. Finally, Avantax Advisory Services Inc. lifted its holdings in shares of Boston Scientific by 17.0% in the first quarter. Avantax Advisory Services Inc. now owns 42,616 shares of the medical equipment provider’s stock valued at $4,299,000 after purchasing an additional 6,200 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

NYSE:BSX opened at $96.77 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $143.46 billion, a P/E ratio of 51.75, a P/E/G ratio of 2.02 and a beta of 0.58. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The business has a fifty day simple moving average of $98.97 and a two-hundred day simple moving average of $102.36.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 175,782 shares of company stock worth $17,742,314 over the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

BSX has been the subject of several recent research reports. The Goldman Sachs Group reiterated a “buy” rating and set a $124.00 price target on shares of Boston Scientific in a report on Wednesday, October 22nd. Truist Financial upped their target price on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Barclays upped their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Finally, Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.